pharma · Lymphoma of B-cell origin · Malignant Solid Tumors
Genmab
Genmab A/S
Genmab A/S is a pharma organization headquartered in Valby, DK. Primary therapeutic focus areas include Lymphoma of B-cell origin, Malignant Solid Tumors, Metastatic or advanced malignant solid tumors, Non-Small Cell Lun
Company details
- Status
- Public
- HQ
- Carl Jacobsens Vej 30, 2500 Valby, DK
- Employees
- 2,847
- Programs
- 29
- Drugs
- 56
- Patents
- 0
GCT1042-01
Phase 2 · small molecule · Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).
GCT1042-01 for Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC). is a Phase 2 program (small_molecule) at Genmab A/S with 1 ClinicalTrials.gov record(s).
Internal code GCT1042-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Genmab A/S
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).
- Status
- active
- Trials
- 1